Program
deucravacitinib
Also written as “BMS-986165”, “Deucravacitinib” and “BMS-986165 Tablet”.
Its studies are mostly in Psoriasis · Lupus Erythematosus, Systemic · Arthritis, Psoriatic · Crohn Disease · Colitis, Ulcerative, led by 2 companies.
Drug pageDeucravacitinib: every studyAll 78 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bristol-Myers Squibbits history only | 5912 open or running | phase 4since Jul 27, 2022 | Oct 3, 2016 | Nov 18, 2026phase 3 · NCT05946941 |
| AbbVieits history only | 10 open or running | phase 4since Mar 21, 2024 | Mar 21, 2024 | none ahead |
Also a collaborator on its studies: Covance.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Not listed one by one: 45 earlier studies, Oct 3, 2016 to Jul 27, 2022.
- Jun 9, 2020Named deucravacitinibINNProposed as its International Nonproprietary Name in WHO's List 123 · before, BMS-986165
- Sep 23, 2022Phase 2 study in Alopecia AreataBristol-Myers Squibb · NCT05556265 · 94 enrolled · United States, Australia, Canada and more
- Nov 8, 20222 phase 3 studies in Lupus Erythematosus, SystemicBristol-Myers Squibb · NCT05617677, NCT05620407
- Jan 16, 2023Phase 4 study in PsoriasisBristol-Myers Squibb · NCT05701995 · 180 enrolled · United States, Puerto Rico
- Jul 7, 2023Phase 3 study in Sjogren's SyndromeBristol-Myers Squibb · NCT05946941 · 774 enrolled · United States, Argentina, Australia and more
- Sep 12, 2023Phase 4 study in Palmoplantar PsoriasisBristol-Myers Squibb · NCT06042920 · 130 enrolled · United States, Argentina, Canada
- Mar 21, 2024AbbVie’s first study: phase 4 study in Moderate Plaque PsoriasisNew to AbbVieAbbVie · NCT06333860 · 393 enrolled · United States, Australia, Belgium and more
- Jun 21, 2024Phase 4 study in Healthy VolunteersBristol-Myers Squibb · NCT06476834 · 8 enrolled · United States
- Aug 21, 2024Phase 1 study in Healthy ParticipantsBristol-Myers Squibb · NCT06566768 · 52 enrolled · United Kingdom
- Jan 22, 2025Phase 1 study in Healthy ParticipantsBristol-Myers Squibb · NCT06851871 · 26 enrolled · United States
- Mar 6, 2025Phase 3 study in Arthritis, JuvenileBristol-Myers Squibb · NCT06869551 · 60 planned · United States, Brazil, Bulgaria and more
- Mar 12, 2025Phase 4 study in Lupus Erythematosus, SystemicBristol-Myers Squibb · NCT06875960 · 35 planned · United States
- May 13, 2025Phase 3 study in PsoriasisBristol-Myers Squibb · NCT06979453 · 366 planned · United States, Argentina, Belgium and more
- Aug 4, 2025Phase 3 study in Plaque PsoriasisBristol-Myers Squibb · NCT07116967 · 3,040 planned · United States, Argentina, Australia and more
- Aug 25, 2026Phase 3 study in Lupus Erythematosus, SystemicBristol-Myers Squibb · NCT07791199 · 2,300 planned
Ahead
- Nov 18, 2026Primary completion: phase 3 study in Sjogren's SyndromeBristol-Myers Squibb · NCT05946941
- Jan 31, 2028Primary completion: phase 4 study in Lupus Erythematosus, SystemicBristol-Myers Squibb · NCT06875960
- Jan 1, 2029Primary completion: phase 3 study in PsoriasisBristol-Myers Squibb · NCT04772079
- Oct 12, 2029Primary completion: phase 3 study in PsoriasisBristol-Myers Squibb · NCT06979453
TargetBeta
“Tyrosine-protein kinase TYK2 negative allosteric modulator”ChEMBL 37, by rule
Other programs on TYK2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ruxolitinibrule | Incyte | phase 4 | 95 |
| tofacitinibrule | Pfizer | phase 4 | 94 |
| upadacitinibrule | AbbVie | phase 4 | 64 |
| filgotinib maleaterule | Eisai | phase 4 | 2 |
| filgotinibrule | Lakefront Biotherapeutics NV | phase 3 | 46 |
| brepocitinibrule | Pfizer | phase 3 | 25 |
| delgocitinibrule | LEO Pharma | phase 3 | 21 |
| D-2570rule | InventisBio | phase 3 | 13 |
| HS-10374 | Hansoh Pharmaceutical Group | phase 3 | 6 |
| TQH3906 | Sino Biopharmaceutical | phase 3 | 6 |
| FXS5626 | Fosun Pharma | phase 3 | 3 |
| TYK2 Inhibitorrule | usynova-pharmaceuticals-ltd | no phase | 1 |
Studies
All 60 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07791199Lupus Erythematosus, Systemic | 3 | Not yet recruiting | Bristol-Myers Squibb | Oct 31, 2030 | 2,300 |
| NCT07116967Plaque Psoriasis · United States, Argentina, Australia and more | 3 | Recruiting | Bristol-Myers Squibb | Jan 16, 2031 | 3,040 |
| NCT06979453Psoriasis · United States, Argentina, Belgium and more | 3 | Recruiting | Bristol-Myers Squibb | Oct 12, 2029 | 366 |
| NCT06875960Lupus Erythematosus, Systemic · United States | 4 | Recruiting | Bristol-Myers Squibb | Jan 31, 2028 | 35 |
| NCT06869551Arthritis, Juvenile · United States, Brazil, Bulgaria and more | 3 | Recruiting | Bristol-Myers Squibb | Mar 6, 2030 | 60 |
| NCT06851871Healthy Participants · United States | 1 | Completed | Bristol-Myers Squibb | Apr 4, 2025 | 26 |
| NCT06566768Healthy Participants · United Kingdom | 1 | Completed | Bristol-Myers Squibb | Jun 13, 2025 | 52 |
| NCT06476834Healthy Volunteers · United States | 4 | Completed | Bristol-Myers Squibb | Nov 2, 2024 | 8 |
| NCT06333860Moderate Plaque Psoriasis · United States, Australia, Belgium and more | 4 | Completed | AbbVie | Mar 19, 2026 | 393 |
| NCT06042920Palmoplantar Psoriasis · United States, Argentina, Canada | 4 | Terminated | Bristol-Myers Squibb | Apr 25, 2025 | 130 |
| NCT05946941Sjogren's Syndrome · United States, Argentina, Australia and more | 3 | Active, not recruiting | Bristol-Myers Squibb | Nov 18, 2026 | 774 |
| NCT05701995Psoriasis · United States, Puerto Rico | 4 | Completed | Bristol-Myers Squibb | Aug 23, 2024 | 180 |
| NCT05620407Lupus Erythematosus, Systemic · United States, Argentina, Australia and more | 3 | Active, not recruiting | Bristol-Myers Squibb | Oct 19, 2026 | 513 |
| NCT05617677Lupus Erythematosus, Systemic · United States, Argentina, Brazil and more | 3 | Active, not recruiting | Bristol-Myers Squibb | Oct 19, 2026 | 516 |
| NCT05556265Alopecia Areata · United States, Australia, Canada and more | 2 | Terminated | Bristol-Myers Squibb | Jan 6, 2024 | 94 |
| NCT05478499Psoriasis · United States, France, Germany and more | 4 | Completed | Bristol-Myers Squibb | Jan 11, 2024 | 154 |
| NCT04949269Healthy Participants · United States | 1 | Completed | Bristol-Myers Squibb | Jan 3, 2022 | 61 |
| NCT04908202Arthritis, Psoriatic · United States, Argentina, Australia and more | 3 | Active, not recruiting | Bristol-Myers Squibb | Oct 10, 2024 | 670 |
| NCT04908189Arthritis, Psoriatic · United States, Argentina, Australia and more | 3 | Active, not recruiting | Bristol-Myers Squibb | Nov 7, 2024 | 729 |
| NCT04877990Crohn Disease · United States, Australia, Canada and more | 2 | Completed | Bristol-Myers Squibb | Aug 29, 2023 | 67 |
| NCT04857034Lupus Erythematosus, Discoid · United States, Argentina, Australia and more | 2 | Active, not recruiting | Bristol-Myers Squibb | Aug 22, 2024 | 74 |
| NCT04772079Psoriasis · Argentina, Australia, Brazil and more | 3 | Recruiting | Bristol-Myers Squibb | Jan 1, 2029 | 153 |
| NCT04671953Healthy Participants · United States | 1 | Completed | Bristol-Myers Squibb | Mar 3, 2021 | 36 |
| NCT04613518Colitis, Ulcerative · United States, Australia, Canada and more | 2 | Completed | Bristol-Myers Squibb | May 31, 2023 | 38 |
| NCT04536961Healthy Volunteers · United Kingdom | 1 | Completed | Bristol-Myers Squibb | Dec 25, 2020 | 56 |
| NCT04305899Healthy Participants · United States | 1 | Completed | Bristol-Myers Squibb | Nov 25, 2020 | 40 |
| NCT04249284Healthy Participants · United States | 1 | Completed | Bristol-Myers Squibb | Mar 15, 2020 | 18 |
| NCT04209699Healthy Participants · United States | 1 | Completed | Bristol-Myers Squibb | Feb 4, 2020 | 18 |
| NCT04167462Psoriasis · China, Korea, Republic of, Taiwan | 3 | Completed | Bristol-Myers Squibb | Mar 8, 2021 | 220 |
| NCT04113668Healthy Participants · United States | 1 | Completed | Bristol-Myers Squibb | Nov 19, 2019 | 48 |
| NCT04086719Healthy Male Volunteers · United States | 1 | Completed | Bristol-Myers Squibb | Oct 29, 2019 | 16 |
| NCT04065932Lupus · United Kingdom | 1 | Completed | Bristol-Myers Squibb | Dec 8, 2019 | 33 |
| NCT04055506Healthy Participants · United States | 1 | Completed | Bristol-Myers Squibb | Sep 21, 2019 | 16 |
| NCT04036435Psoriasis · United States, Australia, Canada and more | 3 | Completed | Bristol-Myers Squibb | Jul 21, 2026 | 1,466 |
| NCT03979248Healthy · Netherlands | 1 | Completed | Bristol-Myers Squibb | Jul 7, 2019 | 21 |
| NCT03956953Autoimmune Diseases · China | 1 | Completed | Bristol-Myers Squibb | Sep 25, 2019 | 135 |
| NCT03934216Colitis, Ulcerative · United States, Australia, Belgium and more | 2 | Completed | Bristol-Myers Squibb | Jun 13, 2021 | 131 |
| NCT03943147Lupus Nephritis · United States, Australia, Belgium and more | 2 | Terminated | Bristol-Myers Squibb | Oct 29, 2020 | 16 |
| NCT03930602Healthy · United States | 1 | Completed | Bristol-Myers Squibb | May 27, 2019 | 16 |
| NCT03924427Psoriasis · Japan | 3 | Completed | Bristol-Myers Squibb | Mar 24, 2021 | 74 |
| NCT03920267Lupus Erythematosus, Systemic · United States, Argentina, Brazil and more | 2 | Completed | Bristol-Myers Squibb | Mar 21, 2025 | 261 |
| NCT03890809Liver Diseases · Czechia, Hungary, Slovakia | 1 | Completed | Bristol-Myers Squibb | Nov 30, 2019 | 32 |
| NCT03890770Renal Insufficiency · United States, Czechia, Hungary and more | 1 | Completed | Bristol-Myers Squibb | Feb 7, 2020 | 44 |
| NCT03881059Active Psoriatic Arthritis · United States, Czechia, Germany and more | 2 | Completed | Bristol-Myers Squibb | Apr 27, 2020 | 203 |
| NCT03873415Psoriasis · United States | 1 | Completed | Bristol-Myers Squibb | May 1, 2019 | 9 |
| NCT03739788Healthy Participants · United Kingdom | 1 | Completed | Bristol-Myers Squibb | Feb 11, 2019 | 8 |
| NCT03751228Healthy Participants · United States | 1 | Completed | Bristol-Myers Squibb | Nov 26, 2018 | 9 |
| NCT03660436Healthy Participants · United States | 1 | Completed | Bristol-Myers Squibb | Oct 10, 2018 | 131 |
| NCT03624127Psoriasis · United States, Canada, China and more | 3 | Completed | Bristol-Myers Squibb | Sep 2, 2020 | 666 |
| NCT03611751Psoriasis · United States, Australia, Canada and more | 3 | Completed | Bristol-Myers Squibb | Nov 29, 2020 | 1,020 |
| NCT03599622Crohn Disease · United States, Australia, Belgium and more | 2 | Terminated | Bristol-Myers Squibb | Dec 12, 2022 | 239 |
| NCT03541564Lupus Erythematosus, Systemic · United States | 1 | Completed | Bristol-Myers Squibb | Sep 4, 2018 | 84 |
| NCT03419910Psoriasis · United States | 1 | Completed | Bristol-Myers Squibb | May 4, 2018 | 54 |
| NCT03402087Arthritis, Psoriatic · Netherlands | 1 | Completed | Bristol-Myers Squibb | Mar 20, 2018 | 30 |
| NCT03262727Lupus Erythematosus, Systemic · United States | 1 | Completed | Bristol-Myers Squibb | Nov 23, 2017 | 49 |
| NCT03254784Lupus Erythematosus, Systemic · United States | 1 | Completed | Bristol-Myers Squibb | Nov 4, 2017 | 49 |
| NCT03252587Lupus Erythematosus, Systemic · United States, Argentina, Australia and more | 2 | Completed | Bristol-Myers Squibb | Jun 29, 2021 | 363 |
| NCT03044873Autoimmune Diseases · United States | 1 | Completed | Bristol-Myers Squibb | Mar 14, 2017 | 20 |
| NCT03004768Psoriasis · United States | 1 | Completed | Bristol-Myers Squibb | Feb 27, 2017 | 6 |
| NCT02931838Psoriasis · United States, Australia, Canada and more | 2 | Completed | Bristol-Myers Squibb | Nov 16, 2017 | 268 |
How it is read
Names in the registry
- “BMS-986165”, 34 entries
- “Deucravacitinib”, 21 entries
- “BMS-986165 Tablet”, 2 entries
- “BMS-986165 Dose A”, 1 entry
- “BMS-986165 Dose B”, 1 entry
Conditions, from the studies’ own filings
- Psoriasis, 16 studies
- Lupus Erythematosus, Systemic, 9 studies
- Arthritis, Psoriatic, 4 studies
- Crohn Disease, 2 studies
- Colitis, Ulcerative, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.